New research from the laboratory of Dr. Elizabeth Leadbetter at the Trudeau Institute may lead to a whole new class of vaccines.Â Leadbetter's lab has discovered new properties of a potential vaccine adjuvant that suggest it could be useful for enhancing protection against a number of different infections. This new data will be published in the January 2012 issue of the journal Nature Immunology in the paper, "iNKT cells direct B cell responses to cognate lipid antigen in an interleukin 21-dependent manner."
Effective vaccines train our bodies to recognize harmful microbes (such as viruses, bacteria and parasites) and typically contain disabled microbes, or even just components of microbes called antigens. Vaccination tricks our bodies into thinking we have been infected by the harmful microbe, triggering an immune response. Ideally, the vaccine produces a long-lived "memory" immune response to the microbe's antigens. This memory allows our bodies to respond more quickly and effectively if we ever become infected by the harmful microbe.
Most human vaccines contain adjuvants -- substances added to the vaccine to improve immune response to the antigens. Adjuvants increase the strength of the immune response and also allow for smaller amounts of antigens to be used in vaccine production.
Immune response to antigens results in the production of antibodies, which are a secreted product of B cells. Antibodies attach to antigens and help our bodies eliminate harmful microbes. Some T cells can help B cells make antibodies. Leadbetter previously discovered that natural killer T (NKT) cells, a special population of T cells, can help B cells make antibodies. NKT cells are special because they recognize lipid (fat) antigens. In contrast, most helper T cells recognize protein antigens. Because many harmful microbes produce unique lipids, Leadbetter hypothesized that directing NKT cells to help B cells could provide a new way to induce antibodies against harmful microbes, which would complement existing vaccine technologies.
Leadbetter's new studies advance her hypothesis that lipid molecules may serve as promising vaccine components. The studies demonstrate that NKT cells can help B cells produce antibodies that recognize lipids, but this does not result in long-lived memory immune responses to the lipid antigens. Second, the studies demonstrate that the lipids, when used as adjuvants to enhance immune responses to more conventional protein antigens, induce memory immune responses against the protein target without inducing a memory response to the lipid itself. Together, these findings suggest a single lipid adjuvant could be used multiple times without losing its effect. The new research also characterizes how NKT cells help B cells produce antibodies when lipids are used as a vaccine adjuvant.
Lipids may become an important new class of adjuvants not only because of their intrinsic properties but also because of their capacity to activate NKT cells. According to Leadbetter, "These cells are really fascinating because they have both innate and adaptive immune cell properties. In other words, they act rapidly, but also specifically. NKT cell activation by certain lipids enhances the activation of other immune cells, thus acting as the body's natural adjuvant."